Single embryo transfer versus multiple transfers in IVF

An IVF result is often described with a single percentage, yet that figure can mean very different things depending on how it was calculated. A live birth rate per embryo transfer is not the same as the chance of a live birth per IVF cycle or across all embryos created during treatment. This distinction matters when comparing single embryo transfer (SET) with multiple-embryo transfer, commonly called double embryo transfer (DET).

For patients in Australia, the decision also involves out-of-pocket costs, access to Medicare rebates, treatment in Melbourne, Sydney, Brisbane or another city, and sometimes travel to Mumbai for donor egg IVF or surrogacy. The safest transfer strategy is therefore a medical decision based on embryo quality, age, treatment history and obstetric risk, rather than a simple preference for transferring the greatest possible number of embryos.

What counts as IVF success

Clinicians need a denominator before comparing IVF outcomes. Implantation rate measures whether embryos attach to the uterine lining, while clinical pregnancy rate confirms a pregnancy through ultrasound. Live birth rate is the clearest measure for a baby’s health, but miscarriage, ectopic pregnancy and pregnancy complications must also be considered when assessing the full impact of a transfer.

A per-transfer live birth rate may appear lower after SET because only one embryo receives the uterine environment. DET can create two potential pregnancies in one attempt, although both embryos do not implant, and one does not automatically develop into a second baby. The additional transfer can also increase miscarriage and multiple-pregnancy risks. Cumulative live birth across a planned series of embryo transfers is often more informative for patients deciding whether to continue treatment.

A fair comparison should consider the patient’s age, whether the embryos are own or donor eggs, fresh or frozen, the embryo’s developmental stage, and the number of embryos available. Clinic experience, embryo grading methods and the use of pre-implantation genetic testing for aneuploidy, or PGT-A, can also change the expected outcome.

Why one embryo is now the preferred default

SET is generally recommended when a patient has a good-quality blastocyst and enough embryos to allow a gradual transfer strategy. It substantially lowers the chance of twins and reduces risks such as preterm birth, low birth weight, gestational diabetes and pregnancy-related hypertension. Those outcomes affect both maternal health and neonatal care.

Australian and New Zealand fertility practice generally favours limiting the number of embryos transferred to reduce multiple pregnancy. This reflects the recognition that IVF should optimise healthy birth rather than pregnancy alone. SET also avoids exposing an embryo to the risks of an unsuccessful twin pregnancy when the intended outcome is a single healthy baby.

The decision can be financially favourable as well. A complicated twin pregnancy may involve additional hospital care, neonatal treatment and time away from work. SET followed by another frozen embryo transfer, when appropriate, can preserve a similar cumulative chance of success while allowing the uterus to recover between attempts. It also gives each embryo a clearer path to implantation without the competition created by transferring two at once.

When multiple-embryo transfer may still fit

DET may be discussed when there are few embryos, their developmental quality is uncertain, or a patient has had repeated implantation failure. It can also be considered in limited situations where transferring two embryos is unlikely to result in twins, such as when only one embryo is suitable for transfer. Even then, the decision should follow a careful review of the embryology report and ultrasound findings.

Age and ovarian reserve deserve consideration, but they do not automatically justify DET. An older patient may have a lower chance of producing a euploid embryo, while a younger patient with an unexpectedly poor response may have only two embryos available. The appropriate question is whether two embryos are genuinely likely to implant and whether the obstetric benefit of avoiding another transfer outweighs the added pregnancy risk.

Cancer treatment creates a different set of considerations because time may be limited and fertility preservation can influence how many embryos are created and frozen. The clinic’s guidance on cancer fertility preservation can help patients understand those options before treatment. Even when several embryos are available, a later SET strategy may preserve the option to transfer one at a time and reduce the likelihood of a multiple pregnancy.

How embryo selection and laboratory quality affect outcomes

Embryo development stage is one of the strongest influences on transfer planning. A hatching or expanded blastocyst may have greater implantation potential than an early cleavage-stage embryo, although grading remains an estimate rather than a guarantee. When several blastocysts are available, SET offers the advantage of selecting the strongest embryo while preserving the others for later use.

PGT-A can provide information about a blastocyst’s chromosomal status, which may help with embryo ranking in some circumstances. It does not guarantee implantation or a healthy birth, and not every embryo is suitable for testing. Decisions about biopsy, testing and transfer should account for the laboratory’s experience, the number of embryos available and whether untested embryos would otherwise have a reasonable chance of success.

Laboratory systems directly affect how accurately embryos are graded, cultured and frozen. At Indo Nippon IVF, decisions across IVF, ICSI, donor egg IVF, egg freezing and embryo transfer can be coordinated within one reproductive medicine team. Ultrasound-guided placement, controlled stimulation protocols, cryopreservation methods and the timing of a frozen embryo transfer can all influence outcomes. Specialist oversight remains essential because embryo transfer is the final clinical step in a process that begins with ovarian stimulation and careful laboratory handling.

Practical realities for Australian patients

IVF in Australia may qualify for Medicare rebates through the Medicare Benefits Schedule, but the assisted reproductive technology items rarely cover the full cost of treatment. Private health insurance often excludes IVF and associated pharmacy, pathology and ultrasound expenses. Patients should request an itemised treatment estimate that includes consultations, scans, medication, embryo storage, genetic testing and the cost of additional transfers.

Patients in Melbourne, Sydney and Brisbane have access to several accredited fertility clinics, which allows meaningful comparison of services. Useful measures include live birth outcomes by age and treatment type, embryo formation rates, laboratory accreditation and continuity of care. Location still affects daily life: interstate treatment can mean repeated travel for injections and scans, time away from employment, partner participation and decisions about storing or transferring frozen embryos when a patient moves.

Some Australians travel to Mumbai for donor eggs, surrogacy or more affordable treatment. Cross-border care requires planning for visas, accommodation, medication access, scans, communication with the clinic, return travel and legal documents. Surrogacy and parentage arrangements also differ between Australian states and territories, so independent legal advice may be needed before committing to treatment. Pet owners travelling overseas can consult a pet-care city resource to identify the type of local services to check, while confirming that any guide applies to Mumbai rather than another destination.

Recommendations for an informed transfer plan

A productive clinic consultation should turn general success figures into a plan specific to the patient’s embryos and medical history. Before approving a transfer, patients can use the following checklist:

• Ask for live birth rates based on the patient’s age, egg source and treatment type, rather than relying only on a headline implantation percentage.
• Request a clear explanation of how many embryos are available, their developmental stage, their grading and whether any are suitable for PGT-A.
• Confirm why SET is proposed and identify the clinical circumstances that could justify changing to DET.
• Establish whether the embryos are fresh or frozen, what the transfer protocol involves and how many additional transfer attempts are financially realistic.
• Review medication, monitoring, storage and complication costs alongside the quoted IVF fee, including the possible Medicare rebates.
• Compare clinics using outcome data, laboratory standards, specialist continuity and transparent policies rather than promotional claims alone.

An appointment with a reproductive medicine specialist can help reconcile the embryology report, uterine assessment, age and previous treatment history. At Indo Nippon IVF, a customised plan can address the balance between transfer numbers, embryo selection and the health of a future pregnancy. Requesting that review before the final transfer decision gives patients a clearer path toward a safe, healthy birth.